SiMPLI

You may also be interested in

Breast cancer screening test

Xemperia flag-ship project is a PCR-based blood test for breast cancer screening. The technology can be adapted to other cancers, immune, inflammatory and cardiovascular diseases. Xemperia's pipeline also includes DNA based nansensors for the ultrasensitive detection of nucleic acids.

Phase II completed

Proclarix

Proclarix® is CE marked, intended for in vitro diagnostic use and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml.

Marketed

SiMPLI & CoMPLI product families

SiMPLI & CoMPLI product families for industrial autonomous automatic TEER (Trans Epithelial Electrical Resistance) measurements of in vitro reconstituted human biological barriers